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ABSTRACT
We hypothesized that plasma-based EGFR mutation analysis for NSCLC may 
be feasible for monitoring treatment response to EGFR TKIs and also predict drug 
resistance. Clinically relevant mutations including exon 19 deletion (ex19del), 
L858R and T790M were analyzed using droplet digital PCR (ddPCR) in longitudinally 
collected plasma samples (n = 367) from 81 NSCLC patients treated with EGFR TKI. 
Of a total 58 baseline cell-free DNA (cfDNA) samples available for ddPCR analysis, 
43 (74.1%) had the same mutation in the matched tumors (clinical sensitivity: 
70.8% [17/24] for L858R and 76.5% [26/34] for ex19del). The concordance rates 
of plasma with tissue-based results of EGFR mutations were 87.9% for L858R and 
86.2% for ex19del. All 40 patients who were detected EGFR mutations at baseline 
showed a dramatic decrease of mutant copies (>50%) in plasma during the first two 
months after treatment. Median progression-free survival (PFS) was 10.1 months 
for patients with undetectable EGFR v 6.3 months for detectable EGFR mutations 
in blood after two-month treatment (HR 3.88, 95% CI 1.48-10.19, P = 0.006). We 
observed emerging resistance with early detection of T790M as a secondary mutation 
in 14 (28.6%) of 49 patients. Plasma-based EGFR mutation analysis using ddPCR can 
monitor treatment response to EGFR TKIs and can lead to early detection of EGFR 
TKIs resistance. Further studies confirming clinical implications of EGFR mutation 
in plasma are warranted to guide optimal therapeutic strategies upon knowledge of 
treatment response and resistance.
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INTRODUCTION 
Non-small cell lung cancer (NSCLC) has a dismal 
prognosis with one of the highest mortality rates among 
cancer types [1, 2]. Patients with NSCLC harboring 
epidermal growth factor receptor (EGFR) mutation 
respond to treatment of EGFR tyrosine kinase inhibitors 
(TKIs) [3, 4]. Large randomized phase III trials comparing 
EGFR TKIs such as gefitinib, erlotinib or afatinib with 
cytotoxic chemotherapy consistently demonstrated higher 
response rates and prolonged progression-free survival 
(PFS) in EGFR mutant NSCLC patients, leading to the 
standard treatment of EGFR TKI as first line therapy 
[5-8]. However, most patients with NSCLC treated with 
EGFR TKIs eventually develop acquired resistance [9, 
10]. Although multiple mechanisms are involved, EGFR 
T790M mutation accounts for more than 50% of the 
acquired TKI resistance [11, 12]. Detection of resistance 
requires acquisition and analysis of tumor tissue at the time 
of resistance to understand the underlying mechanism. 
However, the invasive nature of repeated biopsies makes 
it difficult to obtain from patients particularly those 
with poor performance. Other limitations include tumor 
heterogeneity [13], inaccessibility of re-biopsy due to 
tumor location or tumor containing blood vessel or air 
bronchogram, high incidence of tumor necrosis, and a 
single snapshot in time unable to track dynamic changes 
in the mutation.
The circulating tumor DNA in plasma with its 
non-invasive technology has been used as a surrogate 
for tumor tissues in detecting genetic alterations, thus 
providing molecular evolution of the tumors [14-
17]. Bai et al. showed the difference in response rates 
(59.5% and 23.1%, P = 0.002) for gefitinib between 
patients with and without activating EGFR mutation in 
plasma [18]. Recently, droplet digital polymerase chain 
reaction (ddPCR), a highly sensitive technology has been 
developed for detecting low frequency cancer-associated 
mutations [19]. We hypothesized that plasma-based 
EGFR mutation analysis using ddPCR may be feasible 
in monitoring response and resistance to EGFR TKIs. 
Therefore, we conducted a multi-center prospective study 
to assess dynamic changes in EGFR mutation profile 
using a ddPCR method in longitudinally collected plasma 
samples from NSCLC patients harboring activating EGFR 
mutations treated with EGFR TKIs.
RESULTS
Patient characteristics
From January 2012 to October 2014, 81 EGFR 
mutant NSCLC patients who were treated with gefitinib 
or erlotinib and eventually developed acquired resistance 
were enrolled. The median age was 58.2 years (range, 
32.1-81.1 years), 61.7% were female, and 63.0% were 
never smokers. Over four-fifths of patients (84.0%) had 
stage IV disease, 59.3% had ex19del and 59.3% were 
treated with EGFR TKIs as first-line therapy (Table 1). 
Clinical outcomes
Of total 81 patients, 59 (72.8%) patients achieved 
an objective response. With a median follow-up of 18.8 
months, the median PFS and overall survival (OS) were 
8.1 months (95% CI, 6.2-10.0) and 23.5 months (95% CI, 
19.4-27.6), respectively.
The technical sensitivity and specificity of L858R 
and ex19del assays in the cfDNA
The sensitivity and specificity of the ddPCR assays 
in measuring EGFR mutations in cfDNA were determined 
from 367 plasma samples collected from baseline to every 
8 weeks after EGFR TKI treatment from 81 patients. We 
applied two QC criteria for the results of these plasma 
samples: 1) the droplet number must be greater than 
Table 1: Baseline characteristics (n = 81)
No. of patients %
Age, years
  Median 58.2
  Range 32.1-81.1
Sex
  Male 31 38.3
  Female 50 61.7
Smoking history
  Never smoker 51 63.0
  Former smoker 18 22.2
  Current smoker 12 14.8
Tumor type
  Adenocarcinoma 80 98.8
  Adenosquamous 1 1.2
Tumor stage
  IV 68 84.0
  Postoperative relapse 13 16.0
Type of EGFR mutation
  Exon 19 deletion 48 59.3
  L858R 33 40.7
Line of EGFR TKIs
  First line 48 59.3
  Second line 33 40.7
EGFR TKIs
  Gefitinib 58 71.6
  Erlotinib 23 28.4
Abbreviations: EGFR, epidermal growth factor receptor; 
TKIs, kinase inhibitors 
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9000; 2) the wild type (WT) levels to be greater than 100 
copies/mL. After QC, we excluded two patients and 6 time 
points, resulting in 361 samples from 79 patients (Figure 
1). Among the qualified samples, the lowest level of WT 
cfDNA was 1040 copies/mL, and the median was 4568 
copies/mL (data not shown), suggesting that good quality 
of cfDNA is obtained with the current sample preparation 
procedures. 
Since ddPCR assays are very sensitive in 
quantifying rare mutation events, we were able to detect 
very low MT allele frequency (AF) in the cfDNA for 
both L858R and ex19del mutations. The lowest MT AF 
detected among 57 L858R+ samples was 0.003%, while 
among 113 ex19del+ samples was 0.005% (Figure 2A). 
To test the specificity, we analyzed the results based on 
the mutual exclusivity of the two mutations in the same 
sample. For the L858R assay, we observed no L858L 
mutant copies in the 110 ex19del+ plasma samples (Figure 
2B); for ex19del assay, no ex19del mutant copies were 
detected in the 57 L858R+ samples (Figure 2C), which 
demonstrated 100% of specificity. 
Clinical sensitivity of plasma-based EGFR 
mutation assays and their concordances with 
tissue mutation status
The clinical sensitivity of the EGFR mutation 
detection in plasma was assessed among 58 patients 
whose baseline samples were available. L858R or ex19del 
mutations were detected in 43 patients (Table 2) yielding 
sensitivity of 74.1% (43/58); 70.8% (17/24) for L858R 
and 76.5% (26/34) for ex19del. We assessed the specificity 
based on the mutual exclusivity of L858R mutation and 
ex19del mutation in EGFR mutant tumors. No L858R 
mutation was detected in the ex19del patient plasmas, 
and vice versa. Therefore, the specificity of cfDNA 
L858R assay and ex19del assay was 100% (34/34) and 
Figure 1: Patients exclusion in the analysis based on the availability of the baseline and PD samples, as well as primary 
mutations (L858R, ex19del) detection status (“detectable” vs. “undetectable”). 
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100% (24/24) respectively. The concordance rate between 
cfDNA and tissue was 87.9% for L858R and 86.2% for 
ex19del before treatment. 
We then examined the EGFR mutation detection 
rate in plasma from patients who experienced progressive 
disease (PD). Of 79 patients, 49 patients had plasma 
samples available at the time of progression. Among 49 
patients, L858R and ex19del mutations were detected in 
32 patients, resulting in 65.4% (32/49) clinical sensitivity 
in plasma at disease progression (Figure 1, Table 2). 
We subsequently assessed the detection rate 
of resistance mutation T790M among patients who 
developed PD. As described previously [20], the technical 
background of T790M assay in fresh and FFPE gDNA is 
0.03% and 0.05%, respectively. The quadruplicate repeats 
of the test were implemented in determining the true 
positives of plasma T790M measurements. Among the 
four data points for each sample, only those with at least 
three non-zero readings were considered as positives. With 
these criteria, 50 out of 361 samples were positive in the 
T790M detection. The lowest allele frequency detected 
was 0.017% and the median was 1.24% (Figure 2A). 
Among 49 patients with available samples at the time of 
progression, 14 patients (28.6%) had detectable T790M in 
their plasma. 
Longitudinal monitoring for primary and 
resistance EGFR mutations in patients treated 
with EGFR TKIs
To investigate whether cfDNA mutation level can 
be used to monitor the treatment response and resistance 
longitudinally, we analyzed plasma samples at specified 
times over the course of treatment cycle. Among 79 
patients, five patients who had only one time point and 
four who had neither baseline nor PD data points were 
excluded for analysis (Figure 1). In addition, 24 samples 
collected beyond disease progression were excluded. 
Among 70 patients with more than 1 available time point, 
33 patients had both baseline and PD points, 21 patients 
had only baseline, and 16 had only PD (Figure 1, Table 3). 
The level of L858R copies at baseline were shown 
to be significantly (P = 0.0068) associated with shorter 
PFS. But we did not see the correlation in ex19del 
(Supplementary Figure 1). Among the 54 patients whose 
baseline samples were available for analysis, L858R or 
ex19del mutations were detected in 40 patients’ plasmas 
at the baseline. All 40 patients showed decreased mutant 
DNAs in circulation after EGFR TKI treatment. Of 
note, 34 patients (85.0%) had plasma EGFR mutations 
decreased to the undetectable level (0 copy) during 
the treatment cycle compared to the baseline (Table 
3, Supplementary Figure 2). Intriguingly, there was 
Table 2: Clinical sensitivity and concordance between tissue and cfDNA measurement results
Prior Treatment (n = 58) Disease Progression (n = 49)
cfDNA cfDNA
Tissue L858R+ L858R- Total Ex19del+ Ex19del- Total L858R+ L858R- Total Ex19del+ Ex19del- Total
Positive 17 7 24 26 8 34 11 10 21 21 7 28
Negative 0 34 34 0 24 24 0 28 28 0 21 21
Total 17 41 58 26 32 58 11 38 49 21 28 49
Sensitivity 70.8 76.5 73.7 75.0
Specificity 100 100 100 100
Concordance 87.9 86.2 79.6 85.7
Abbreviations: cfDNA, cell-free DNA; Ex19del, exon 19 deletion
Figure 2: Technical sensitivity and specificity of cell-free plasma DNA using ddPCR assay (n = 79). A. distribution of 
frequency of alleles according to the EGFR mtuations (ex19del, L858R, and T790), B. detection of L858R mutant alleles in ex19del- 
negative and ex19del- positive population, and C. detection of ex19del mutant alleles in L858R-negative and L858R-positive population.
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a significant difference in PFS between patients with 
undetectable EGFR mutation and detectable EGFR 
mutation (10.1 months vs 6.3 months; HR 3.88, 95% CI 
1.48-10.19, P = 0.006; Figure 3A). Similarly, the median 
OS of patients with undetectable EGFR and detectable 
EGFR were 23.7 and 11.2 months, respectively (HR 5.97, 
95% CI 2.04-17.47, P = 0.001; Figure 3B). Of 49 patients 
with PD plasma samples, 15 patients (30.6%) showed 
increased mutation level at the PD time point, and 12 
patients (24.5%) showed increased mutation level about 2 
to 12 months earlier than the PD time point, as judged by 
the primary mutation L858R or ex19del (Figure 1, Table 
3). 
Among 49 patients with available samples at the 
time of progression, the T790M mutation was detected 
in 8 patients (16.3%) as early as 2 to 12 months prior 
to radiological progression: the remaining 6 patients 
(12.2%) developed T790M mutation at the time of PD 
(Supplementary Figure 3). It is noteworthy that one patient 
had detectable prior treatment T790M mutation. Although 
plasma ex19del and T790M levels were decreased with 
clinical response after gefitinib treatment in patients with 
de novo T790M mutation, brain and bone metastases 
occurred after 6 months of gefitinib treatment. 
The tumor volume was assessed using Chest CT 
scans by radiologists (HY Lee, and SH Bak) for each 
patient every eight weeks. Figure 4 shows the levels 
of circulating two EGFR primary mutations and the 
corresponding tumor volumes over the course of treatment 
to disease progression. In patients whose plasma T790M 
mutation was detected at the time of progression, T790M 
was generally at slightly lower levels than the primary 
mutations. In one patient (#2) with a response to gefitinib, 
an increase in plasma ex19del and T790M levels was 
seen during the development of bone metastasis (Figure 
4). Two patients (#10 and #88) showed an increase in 
Figure 3: Survival curves for the 40 patients treated with EGFR TKIs. A. Progression-free survival (PFS) and B. overall 
survival (OS) by cfDNA status at lowest level during the treatment. 
Table 3: Dynamic monitoring of patient response to therapy by cfDNA
Patient Total(n=70*)
cfDNA mutation at
baseline (n=40)
L858R/ex19del
Dynamic monitoring of cfDNA mutation
L858R/ex19del T790M
Decrease
not zero
Decrease 
to zero
Increase at 
progression
Increase 
earlier than 
progression
Increase at 
progression
Increase 
earlier than 
progression
B+P+ 33 24 3 21 10 10 4 5
B+P- 21 16 3 13
B-P+ 16 5 2 2 3
Abbreviations: cfDNA, cell-free DNA; Ex19del, exon 19 deletion 
Available samples: B+, available at baseline; P+, available at progression
* Among the 79 patients, 5 patients who had only one time point and 4 patients who had neither baseline nor PD data point 
data excluded for time course analysis. 
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copy number of both plasma L858R and T790M before 
RECIST-defined progression, 11 months and 2 months, 
respectively (Figure 4). 
DISCUSSION
The development of acquired resistance to 
anticancer therapy derives from clonal evolution and 
selection [21, 22]. Thus, serial biopsies for the tumor 
are required to identify the underlying drug resistance 
mechanism and potential therapeutics to overcome or 
prevent it. Moreover, monitoring treatment response 
accompanied by mutations in the tumor genome may be 
needed to evaluate the potential benefits of targeted cancer 
therapies and subsequently determine and tailor optimal 
treatment strategies for patients. However, detection 
of EGFR mutations in NSCLC patients using sampling 
tumor tissues has significant limitations including tumor 
heterogeneity and difficulty in obtaining samples. As 
a non-invasive liquid biopsy capable of identifying 
molecular changes, genomic analysis of circulating tumor 
DNA released from cancer cells into blood has been 
proposed to determine real-time genomic landscapes of 
the tumor without additional burden and risk to patients 
[23]. 
Although several studies have suggested that cfDNA 
from patients with cancer can be used to detect mutations 
with high sensitivity [24-26], the detection of samples with 
low mutation fractions has uncertain clinical significance 
[27]. The study by Zhang et al. [20] demonstrated the 
feasibility of applying the ddPCR system to detect EGFR 
mutation and the advantage of ddPCR in the detection of 
samples with low EGFR mutation fractions. 
In the present study, we demonstrated 74.1% 
sensitivity and 100% specificity of a plasma assay for 
EGFR mutations using ddPCR. The concordance rates of 
L858R and ex19del were 87.9% and 86.2%, respectively. 
Our results are consistent with those from previous studies 
[28, 29] and support the use of this technology in clinical 
practice for making treatment decisions especially for 
patients not amenable to tissue biopsy. The relatively 
lower clinical sensitivity of EGFR mutations in patients at 
the time of disease progression (65%) is likely attributed to 
the tumor shrinkage after drug treatment and the collection 
time of plasma samples near or at the PD stage. 
In the current study with a total of 40 patients whose 
plasma collections from baseline were available for a 
longitudinal analysis, we observed a marked decrease in 
plasma EGFR mutations during the first 2 months in all 
patients after EGFR TKI treatment. More intriguingly, 34 
patients (85%) had EGFR level decreased to undetectable 
level with longer PFS and OS than those with detectable 
EGFR in blood. In addition, the levels of both EGFR 
primary and resistance mutations in plasma increased 
Figure 4: Longitudinal L858R, ex19del and T790M levels in plasma along with tumor volume measured by CT scan. 
Arrow (red) shows increased copy number of both plasma L858R and T790M before RECIST-defined progression in two patients (#10 and 
#88). (Unit of x-axis: time point of acquisition of plasma (every 8 weeks). 0 = baseline).
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progressively during disease progression. These findings 
suggest that longitudinal monitoring of plasma EGFR 
mutation levels can be a good predictive biomarker. 
Sorensen et al. [30] and Mok et al. [31] also showed the 
predictive value of serial assessment of cfDNA during 
treatment. To the best of our knowledge, this is the first 
study that evaluates longitudinal measurements of tumor 
volume with serial assessments of tumor DNA in blood 
for NSCLC patients treated with EGFR TKIs. The trend 
of mutation titer in plasma was well correlated with the 
tumor volume as measured by CT scan. 
EGFR T790M is one of the most common mutations 
associated with acquired resistance to EGFR TKIs in 
NSCLC patients, which accounts for 50-60% [11, 32]. At 
present, the presence of T790M mutation is determined 
upon taking a new biopsy of the tumor from the patients at 
the time of progression. Given the limitations of repeated 
invasive biopsies, several studies were investigated to 
analyze acquired resistance to cancer therapies by non-
invasive methods using plasma DNA [29, 33, 34]. We 
found that 14 patients (28.6%) among a total of 49 patients 
harbored resistance mutation T790M in the blood during 
EGFR TKIs treatment, which is similar to the study by 
Sakai et al. [35] in which T790M mutation was detected 
in 21 (30%) of 75 plasma samples from patients with 
clinical PD using the single allele base extension reaction 
(SABER) assay. It is noteworthy that the T790M mutant 
alleles were detectable in the blood of EGFR TKIs-
treated patients as early as 12 months before radiographic 
documentation of disease progression in our study. 
This suggests that cfDNA may have important clinical 
implications as a useful surrogate biomarker of therapeutic 
response and be used to identify the development of 
resistant mutation, especially in early detection before it 
becomes clinically detectable. Furthermore, the detection 
of T790M mutation in cfDNA would be clinically 
useful for patients who are not amendable to repeated 
biopsies. Given the promising clinical results of several 
3rd generation EGFR TKIs in patients with T790M 
mutation [36-38], these treatment therapies will soon 
be available and accessible warranting effective clinical 
diagnostics to evaluate drug resistance. However, it still 
remains undetermined whether T790M mutation detected 
in cfDNA prior to clinically overt progression will 
change treatment decisions because patients harboring 
this mutation are usually indolent and EGFR TKI can be 
continued beyond progression [39]. Therefore, the clinical 
impact of early detection of the resistance mutation in 
plasma DNA needs to be elucidated in the near future. 
In conclusion, this study demonstrated that plasma 
EGFR assay using ddPCR can be feasible and effective 
in monitoring treatment response to EGFR TKIs, and 
detecting the underlying mechanism of resistance in a 
noninvasive method. Determining the genetic landscapes 
of tumors through noninvasive real-time mutational 
profiling may have significant clinical implications in 
identifying and guiding optimal treatment strategies, 
particularly when T790M mutation is detected in the 
blood. 
MATERIALS AND METHODS
Study design
This was an exploratory study to evaluate the 
potential utilization of EGFR mutations in plasma using 
ddPCR in monitoring treatment response and resistance 
among NSCLC patients harboring EGFR activating 
mutations treated with EGFR TKIs. Eligible patients had 
a diagnosis of advanced or recurrent NSCLC harboring 
activating EGFR mutation (exon 19 deletion or L858R) 
who had progressed on gefitinib or erlotinib. The analysis 
of EGFR (exon 18-21) mutations for tumor tissues 
obtained from either diagnostic or surgical procedures was 
performed prior to TKI treatment by direct sequencing or 
PNA-clamp method (Panagene Inc., Daejeon, Korea). 
Patients were treated with gefitinib (250 mg po daily) or 
erlotinib (150 mg po daily) at the discretion of treating 
physicians. Appropriate imaging measures including CT 
scans of the chest were performed every two cycles (8 
weeks) and evaluated treatment response according to 
Response Evaluation Criteria in Solid Tumors (RECIST 
version 1.1). All patients provided written informed 
consent. This study was performed in accordance with 
the Declaration of Helsinki and approved by Institutional 
Review Board for Human Research at each institute. 
The primary objective of this exploratory analysis 
was to assess the diagnostic utility of the blood test for 
sensitivity, specificity, concordance rate, and comparison 
with tumor tissue EGFR mutation status. The secondary 
objectives included identifying the time difference 
between development of genetic aberrancy associated with 
resistance in plasma and overt clinical progression.
Sample collection and DNA extraction
Plasma samples were prospectively obtained 
before treatment and every 8 weeks post-treatment until 
development of disease progression for cell-free DNA 
(cfDNA) EGFR ddPCR testing. Blood was collected 
into one 10-mL EDTA-containing vacuum tube and 
was centrifuged at 1500 rpm for 15 minutes within 4 
hours of collection. The supernatants were collected and 
centrifuged at 1500 rpm for 15 minutes. The plasmas were 
transferred to 1.5-mL Eppendorf tubes and stored at -70°C 
until DNA extraction. The cfDNA was extracted from 1-2 
mL of plasma using QIAamp Circulating Nucleic Acid Kit 
(Qiagen) according to the manufacturer’s instructions. 
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Droplet digital PCR detection of EGFR mutations 
in plasma cfDNA
Primers and probes were custom synthesized 
by Thermo Fisher and the sequences were reported 
previously [28]. Briefly, the ddPCR assay was conducted 
by droplets generation using QX200 generator (Bio-
Rad Laboratories, Inc., Hercules, CA, USA), followed 
by endpoint PCR reactions using C1000 (Bio-Rad) and 
droplet flow cytometry readings using QX200 reader (Bio-
Rad). Analyzed data were processed using QuantaSoft 
(Bio-Rad) software. Ex19del assay covers all deletion 
mutations in the exon 19. Detailed procedures can be 
found elsewhere [20]. 
Measurement of tumor volume 
Considering the recent studies that the conventional 
RECIST-based assessment alone does not fully 
characterize response and progression in genomically 
characterized patients [40, 41], we further explored the 
volumetric tumor response during TKI therapy. All CT 
image data were reconstructed with a section thickness of 
1.25 mm using soft-tissue algorithms. For each measurable 
lesion, volume measurements were performed with a 
semi-automated segmentation method using MRIcro 
(version 1.40, Chris Rorden, University of Nottingham, 
Great Britain). Using in-house software, the computer 
automatically calculated the volume (cm3) by multiplying 
the number of voxels segmented by the unit volume of a 
voxel. A sum of the volume for all target lesions at each 
time-point was used for the analysis.
Statistical analysis
Sensitivity was calculated as the number of samples 
positive in both tissue and plasma out of the positive 
tissue samples, whereas specificity was calculated from 
the number of plasma- and tissue-negative samples out of 
the total negative tissue samples. Concordance rate was 
calculated as the number of samples positive in both tissue 
and plasma, plus the number of samples negative in both 
tissue and plasma, out of the total number of matched 
samples. Survival estimates were calculated according to 
Kaplan-Meier method. Cox regression methods were used 
for biomarker at baseline associated with PFS. Statistical 
analysis was performed using SAS 9.4 (SAS Institute Inc, 
Cary, NC) and R version 3.0.3 (Vienna, Austria; http://
www.R-project.org/). A 2-sided P-value of < 0.05 was 
considered statistically significant.
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